Latest 10-K annual reports

FOXO Technologies amends its termination agreement with KR8 AI to clarify the scope of the termination, focusing on financial obligations rather than the entire agreement.

TriSalus Life Sciences reports a 59% increase in revenue for 2024, driven by its TriNav Infusion System, while continuing to develop its immunotherapeutic, nelitolimod.

SUNation Energy's 10-K filing reveals delisting concerns, material weaknesses in internal controls, and a strategic shift towards Bitcoin amidst ongoing financial challenges.

Yuenglings Ice Cream Corporation, rebranding as a technology holding company, reports a net profit of $4.39 million for 2024, driven by fair market value changes and debt extinguishment gains, while strategically divesting its ice cream assets.

Oncotelic Therapeutics' 2024 annual report details ongoing efforts to develop cancer treatments, manage financial constraints, and advance strategic partnerships, particularly through its joint venture GMP Biotechnology.

Eyenovia is exploring strategic alternatives and cutting costs after a negative clinical trial result, raising concerns about its ability to continue as a going concern.

Royalty Management Holding Corporation files an amendment to its 2024 annual report to include a compensation clawback policy.

Balance Labs, a consulting firm for startups, reported a net loss of $528,223 for the year ended December 31, 2024, and its independent auditor has raised substantial doubt about its ability to continue as a going concern.

Banzai International, Inc. details its financial performance for fiscal year 2024, highlighting strategic acquisitions, Nasdaq listing compliance, and ongoing efforts to manage operating losses and enhance shareholder value.

Nauticus Robotics reports a substantial net loss for 2024, signaling a challenging year as the company transitions towards commercializing its autonomous subsea robotic solutions.

LanzaTech Global's FY2024 results reveal ongoing net losses and substantial doubt about its ability to continue as a going concern, while the company evaluates a non-binding take-private proposal from Carbon Direct Capital.

Cactus Acquisition Corp. 1 Ltd.'s annual report reveals delisting from Nasdaq, a business combination agreement with Tembo e-LV B.V., and substantial doubt about its ability to continue as a going concern.

AppYea Inc.'s Form 10-K reveals a significant increase in net loss for the fiscal year ended December 31, 2024, and raises substantial doubt about the company's ability to continue as a going concern.

Iveda Solutions reports a slight decrease in revenue for 2024, accompanied by an increased net loss, as the company navigates a strategic shift towards AI and IoT technologies.

Vivakor's 2024 annual report shows revenue growth driven by acquisitions, but significant net losses and an accumulated deficit raise concerns about the company's ability to continue as a going concern.

TransCode Therapeutics faces financial hurdles but progresses with clinical trials and preclinical programs in RNA-based cancer therapies.

Toppoint Holdings Inc.'s 2024 annual report reveals a revenue decrease due to lower scrap paper export volumes, offset by strategic expansions and new partnerships.

Cosmos Health Inc. reports a net loss of $16.18 million on revenue of $54.43 million for fiscal year 2024, while addressing concerns about its ability to continue as a going concern.

ESG Inc. reports a 70.2% increase in net operating revenue for the year ended December 31, 2024, driven by expanded capacity and sales of Phase III compost and processed mushroom seasoning powder.

Akari Therapeutics shifts focus to oncology with its ADC platform following a merger, while acknowledging significant financial risks and material weaknesses in internal controls in its recent 10-K filing.

PAID Inc. announces a net income of $763,592 for 2024, primarily driven by growth in its shipping coordination and label generation services.

Abpro Holdings' 10-K filing reveals a restatement of prior financials due to accounting errors, raising concerns about the company's ability to continue as a going concern and impacting investor confidence.

CERo Therapeutics' 2024 10-K filing reveals ongoing losses, clinical trial advancements, and substantial doubt about its ability to continue as a going concern.

Bukit Jalil Global Acquisition 1 Ltd. reports its 2024 financial results in a Form 10-K filing, highlighting a proposed business combination with GIBO and ongoing concerns about its ability to continue as a going concern.

Saker Aviation Services reports a decrease in net income for FY 2024 and the termination of its Downtown Manhattan Heliport concession agreement, prompting a search for alternative revenue streams.

Greenwich LifeSciences focuses on its Phase III clinical trial, Flamingo-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, while reporting a net loss of $15.8 million for 2024.

BioSig Technologies reports its annual results on Form 10-K, highlighting ongoing efforts to regain Nasdaq compliance amidst financial challenges and a potential delisting.

OneMedNet Corporation reports a net loss of $10.1 million for 2024 and expresses substantial doubt about its ability to continue as a going concern.

Borealis Foods Inc.'s 2024 10-K filing reveals a strategic shift towards higher-margin products amidst financial uncertainties and a going concern warning.

WidePoint Corporation's 2024 10-K filing reveals a significant revenue increase driven by carrier and managed services, but also highlights ongoing concerns about contract renewals and internal control weaknesses.